Caroline Dorrepaal
Leiden, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the RSV L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: February 02, 2026
Do we understand voiding dysfunction in women? Current understanding and future perspectives: ICI-RS 2017.
Journal: Neurourology and urodynamics
Published: October 30, 2017
What are the additional signs and symptoms in patients with detrusor underactivity and coexisting detrusor overactivity?
Journal: Neurourology and urodynamics
Published: October 26, 2017
Signs and symptoms that distinguish detrusor underactivity from mixed detrusor underactivity and bladder outlet obstruction in male patients.
Journal: Neurourology and urodynamics
Published: October 26, 2017
A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder.
Journal: Clinical pharmacology and therapeutics
Published: May 12, 2015
Signs and Symptoms of Detrusor Underactivity: An Analysis of Clinical Presentation and Urodynamic Tests From a Large Group of Patients Undergoing Pressure Flow Studies.
Journal: European urology
Published: April 26, 2015
Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men.
Journal: International journal of clinical pharmacology and therapeutics
Published: April 24, 2014
Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial.
Journal: BMC urology
Published: June 14, 2013
Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.
Journal: International journal of clinical practice
Published: February 20, 2013
Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
Journal: European urology
Published: September 07, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026